Abstract:Human allogeneic pancreatic islet transplantation is a life-changing treatment for patients with severe Type 1 Diabetes (T1D) who suffer from hypoglycemia unawareness and high risk of severe hypoglycemia. However, intensive immunosuppression is required to prevent immune rejection of the graft, that may in turn lead to undesirable side effects such as toxicity to the islet cells, kidney toxicity, occurrence of opportunistic infections, and malignancies. The shortage of cadaveric human islet donors further limits islet transplantation as a treatment option for widespread adoption. Alternatively, porcine islets have been considered as another source of insulin-secreting cells for transplantation in T1D patients, though xeno-transplants raise concerns over the risk of endogenous retrovirus transmission and immunological incompatibility. As a result, technological advancements have been made to protect transplanted islets from immune rejection and inflammation, ideally in the absence of chronic immunosuppression, to improve the outcomes and accessibility of allogeneic islet cell replacement therapies. These include the use of microencapsulation or macroencapsulation devices designed to provide an immunoprotective environment using a cell-impermeable layer, preventing immune cell attack of the transplanted cells. Other up and coming advancements are based on the use of stem cells as the starting source material for generating islet cells 'on-demand'. These starting stem cell sources include human induced pluripotent stem cells (hiPSCs) that have been genetically engineered to avoid the host immune response, curated HLA-selected donor hiPSCs that can be matched with recipients within a given population, and multipotent stem cells with natural immune privilege properties. These strategies are developed to provide an immune-evasive cell resource for allogeneic cell therapy. This review will summarize the immunological challenges facing islet transplantation and highlight recent bio-engineering and cell-based approaches aimed at avoiding immune rejection, to improve the accessibility of islet cell therapy and enhance treatment outcomes. Better understanding of the different approaches and their limitations can guide future research endeavors towards developing more comprehensive and targeted strategies for creating a more tolerogenic microenvironment, and improve the effectiveness and sustainability of islet transplantation to benefit more patients.

Fusion of blood vessel organoids with human pancreatic islets improves insulin response over time

In Vitro Expansion of Pancreatic Islet Clusters Facilitated by Hormones and Chemicals.

Improvement of islet transplantation by the fusion of islet cells with functional blood vessels

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

A vascularized 3D model of the human pancreatic islet for ex vivo study of immune cell-islet interaction

Biofabrication of a vascularized islet organ for type 1 diabetes

Development of a Bioartificial Vascular Pancreas

Bioengineering and vascularization strategies for islet organoids: advancing toward diabetes therapy

Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model

Decellularized Whole-Organ Pre-vascularization: A Novel Approach for Organogenesis

Human Expandable Pancreatic Progenitor–derived Β Cells Ameliorate Diabetes

3D printed VEGF-CPO biomaterial scaffold to promote subcutaneous vascularization and survival of transplanted islets for the treatment of diabetes

Biomimetic Artificial Islet Model with Vascularized Microcapsule Structures for Durable Glycemic Control

Pancreatic islets seeded in a novel bioscaffold forms an organoid to rescue insulin production and reverse hyperglycemia in models of type 1 diabetes

Brown Adipose Tissue as a Unique Niche for Islet Organoid Transplantation: Insights From In Vivo Imaging

A 3D-Printed Microdevice Encapsulates Vascularized Islets Composed of Ipsc-Derived Β-Like Cells and Microvascular Fragments for Type 1 Diabetes Treatment

Co-transplantation of Islets-Laden Microgels and Biodegradable O2-Generating Microspheres for Diabetes Treatment

Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation

Development of scaffold-free vascularized pancreatic beta-islets in vitro models by the anchoring of cell lines to a bioligand-functionalized gelatine substrate

Efficient vascular and neural engraftment of stem cell-derived islets